Loading...
AVHHL
OTCM
Market cap388mUSD
Nov 12, Last price  
3.50USD
Name

AVITA Medical Inc

Chart & performance

D1W1MN
OTCM:AVHHL chart
P/E
—
P/S
1.21
EPS
—
Vol. 1Y
1,516.94%
Shs. 5Y
6.55%
Rev. 5Y
19.63%
Div Yld LY
—
Div Yld TTM
—
Revenues
72m
+11.45%
862,1091,253,2942,192,5642,807,3953,118,3433,430,6933,042,9572,855,792997,0881,342,8891,541,6691,704,6057,829,37014,263,00029,232,00033,025,00034,421,00050,143,00064,251,00071,610,000
Net income
-49m
L-21.44%
-15,066,551-12,141,907-5,179,074-5,932,407-1,950,268-7,498,8450-5,478,625-10,339,926-13,766,483-15,031,095-23,367,245-35,902,972-42,030,000-26,583,000-25,142,000-26,665,000-35,381,000-61,845,000-48,587,000
CFO
-31m
L-36.26%
-8,300,917-3,443,062-4,318,025-1,688,546-2,693,795-4,346,960-8,039,010-6,755,570-7,017,968-7,300,956-8,426,790-12,955,454-27,532,954-22,747,000-25,901,000-18,037,000-19,090,000-38,011,000-48,939,000-31,195,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Key people

James Corbett
President, Chief Executive Officer, Executive Director · since 2022
David O'Toole
Chief Financial Officer · since 2023
Chief Legal and Compliance Officer, Corporate Secretary · since 2024
Joseph Woody
Non-Executive Director · since 2026
Michael Tarnoff
Independent Director · since 2025
Jeremy Cook
Independent Non-Executive Director · since 2015
Suzanne Crowe
Independent Non-Executive Director · since 2016
Independent Non-Executive Director · since 2023
Independent Non-Executive Director · since 2021
Cary Vance
Independent Non-Executive Director · since 2023
IPO date
Mar 18, 2012
Employees
126
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT